Sugi Predict

Sugi Predict / Compounds / SCHEMBL1290158

SCHEMBL1290158

SCHEMBL1290158

CC(C)(C)OC(=O)NCc1ccc(B2OC(C)(C)C(C)(C)O2)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.57
▸ WDR77 Q9BQA1 1/20 0.57
▸ ROCK1 Q13464 1/20 0.48
▸ AAK1 Q2M2I8 2/20 0.47
▸ BACE1 P56817 1/20 0.43
▸ BACE2 Q9Y5Z0 1/20 0.43
▸ HIF1A Q16665 3/20 0.39
▸ DGAT1 O75907 1/20 0.39
▸ KDM4A O75164 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ NR1H4 Q96RI1 1/20 0.37
▸ RPS6KA1 Q15418 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.36
▸ LPL P06858 1/20 0.35
▸ LIPG Q9Y5X9 1/20 0.35
▸ F2 P00734 1/20 0.35
▸ F11 P03951 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490524 0.91 PRMT5 (0.57) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL15092253 0.89 PRMT5 (0.51) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL28616950 0.88 ROCK1 (0.52) PRMT5WDR77ROCK1AAK1HIF1A
SCHEMBL16793978 0.87 PRMT5 (0.58) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL16794372 0.87 PRMT5 (0.56) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL30428827 0.86 PRMT5 (0.57) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL2699076 0.86 PRMT5 (0.57) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL23336972 0.86 PRMT5 (0.55) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL29418380 0.86 PRMT5 (0.55) PRMT5WDR77ROCK1AAK1BACE1
SCHEMBL23336721 0.85 PRMT5 (0.56) PRMT5WDR77ROCK1AAK1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 — — US disclosed
EP-4429770-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 — — EP disclosed
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 — — US disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 — — EP disclosed
WO-2023086521-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 — — WO disclosed
WO-2023086521-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 — — WO disclosed
WO-2022235945-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. (US) 2022-11-10 — — WO disclosed
EP-3204382-B1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-12-01 — — EP disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
US-20130245021-A1 IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2013-09-19 — — US disclosed
US-20130245021-A1 IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2013-09-19 — — US disclosed
US-20130245021-A1 IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2013-09-19 — — US disclosed
WO-2013134219-A1 IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF LEXICON PHARMACEUTICALS, INC. (US) 2013-09-12 — — WO disclosed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 — — EP disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 — — WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 — — WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245021-A1 IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE IRAK2, IRAK1, GRB2 PRMT5 739/4885WDR77 858/4885ROCK1 1816/4885
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN PRMT5 1660/4885WDR77 652/4885ROCK1 1694/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN PRMT5 1487/4885WDR77 2039/4885ROCK1 363/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B PRMT5 3632/4885WDR77 1926/4885ROCK1 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.